James Tribble is a Lecturer in the Wolfson Sensory, Pain and Regeneration Centre, School of Neuroscience, Institute of Psychiatry, Psychology and Neuroscience at King's College London.

His lab is investigating metabolic dysfunction, inflammation, and the interplay of these in neurodegenerative disease to develop neuroprotective therapies. They are particularly focused on glaucoma, one of the most common neurodegenerative diseases, which causes irreversible blindness.

James' research spans the lab bench to the patient bedside, using the eye as an accessible model CNS tissue to make fundamental neuroscience discoveries, through to translating findings into clinical trials in patients.

His neuroprotective strategies are broadly categorised into metabolic supplements which enhance or correct metabolic changes in disease (which can be taken rapidly to trial), data-driven repurposing of existing drugs with known safety data, and refining these into gene therapies that could provide targeted, lasting protection.

Please see his Research Staff Profile for more detail

Key collaborators 

• Dr Richard Eva, King's College London
• Professor Pete Williams, Centre for Eye Research Australia
• Professor Anthony Khawaja, UCL Institute of Ophthalmology

Key publications

• Tribble et al., Dysfunctional one-carbon metabolism identifies vitamins B6, B9, B12, and choline as neuroprotective in glaucoma. Cell Reports Medicine. 
• Tribble et al., NMNAT2 is a druggable target to drive neuronal NAD production. Nature Communications. 
• Rombaut et al., Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma. Molecular Brain.
• Tribble et al., Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biology.